SESSION TITLE: Chest Infections Posters: Tuberculosis
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM
PURPOSE: Hemodialysis (HD) patients are at increased risk of reactivation of latent tuberculosis infection (LTBI) compared with the general population. QuantiFERON-TB Gold (QFT-G) for LTBI detection is more promising than tuberculin skin test (TST) in HD patients. However, their prognostic value for progression from LTBI to active tuberculosis (TB) has yet to be established.
METHODS: The study enrolled 100 HD patients and 90 age-matched, healthy controls. The TST and new interferon-γ blood tests, QuantiFERON-TB Gold (QFT-G) were performed. Five patients were lost during the follow-up period. 95 patients and all the healty conntrols were followed up 5 years for active TB disease.
RESULTS: Compared to the healthy controls, a high prevalence of LTBI was found in the ESRD patients by TST (34 %), QFT-G (43 %). Four (4%) HD patients progressed to TB disease within the 5-year follow-up. In HD patients, sensitivity, specificity, positive and negative predictive values of QFT-G and TST for active TB was 100 % and 25 %, 62% and 67%, 10% and 3 %, and 100% and 95%, respectively. Roc anaysis revealed that the results are significantly different (p=0.04).
CONCLUSIONS: QuantiFERON TB-2G test is a more useful diagnostic method than TCT for detecting those who will progress to active TB in HD patients.
CLINICAL IMPLICATIONS: QuantiFERON TB-2G was the more accurate method for identifying those truly infected with Mycobacterium tuberculosis, even in BCG-vaccinated individuals
DISCLOSURE: The following authors have nothing to disclose: akif özgül
No Product/Research Disclosure Information